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ABSTRACT
Introduction: Breast feeding can promote positive
long-term and short-term health outcomes in infant
and mother. The UK has one of the lowest
breastfeeding rates (duration and exclusivity) in the
world, resulting in preventable morbidities and
associated healthcare costs. Breastfeeding rates are
also socially patterned, thereby potentially contributing
to health inequalities. Financial incentives have been
shown to have a positive effect on health behaviours in
previously published studies.
Methods and analysis: Based on data from earlier
development and feasibility stages, a cluster (electoral
ward) randomised trial with mixed-method process and
content evaluation was designed. The ‘Nourishing Start
for Health’ (NOSH) intervention comprises a financial
incentive programme of up to 6 months duration,
delivered by front-line healthcare professionals, in
addition to existing breastfeeding support. The
intervention aims to increase the prevalence and duration
of breast feeding in wards with low breastfeeding rates.
The comparator is usual care (no offer of NOSH
intervention). Routine data on breastfeeding rates at 6–
8 weeks will be collected for 92 clusters (electoral wards)
on an estimated 10 833 births. This sample is calculated
to provide 80% power in determining a 4% point
difference in breastfeeding rates between groups. Content
and process evaluation will include interviews with
mothers, healthcare providers, funders and
commissioners of infant feeding services. The economic
analyses, using a healthcare provider’s perspective, will
be twofold, including a within-trial cost-effectiveness
analysis and beyond-trial modelling of longer term
expectations for cost-effectiveness. Results of economic
analyses will be expressed as cost per percentage point
change in cluster level in breastfeeding rates between trial
arms. In addition, we will present difference in resource
use impacts for a range of acute conditions in babies
aged 0–6 months.
Ethics and dissemination: Participating organisations
Research and Governance departments approved the
study. Results will be published in peer-reviewed journals
and at conference presentations.
Trial registration number: ISRCTN44898617; Pre-
results.
INTRODUCTION
Breast feeding
The WHO1 recommends that babies are
exclusively breast fed until 6 months, with
breast feeding (BF) continuing for up to
2 years after solid foods have been introduced.
This recommendation is supported by all four
UK Departments of Health and is based on
evidence regarding the long-term and short-
term beneﬁts of BF.2 3 Despite this policy pos-
ition, and an increase in numbers of women
starting to breast feed,4 6–8-week BF rates in
the UK have remained low for several decades
in contrast to some other developed countries
(eg, Norway, Sweden) where the majority of
women breast feed for at least 2 months and
many for longer. Because infant feeding is
socially patterned with women from low-
income groups having the lowest rates, low BF
rates also have a serious negative impact on
inequalities in health.
Financial incentives for behaviour change
Financial incentives have been shown to be
effective in promoting a range of positive
health behaviours5 including adopting a
healthy diet.6 Women on unemployment
beneﬁt in the Quebec province of Canada
have routinely been offered ﬁnancial incen-
tives ($55 per month) for BF since the
mid-1990s,7 but there has been no formal
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evaluation of this or any other ﬁnancial incentive
scheme for BF.
If ﬁnancial incentives were found to be acceptable,
effective in increasing BF rates and cost-effective, this
would have implications for future health policy. For
example, Pokhrel et al8 and Renfrew et al 9 estimate that
over £17 million could be saved each year in the UK,
through reduced hospital admissions and fewer visits to
general practitioners (GPs) relating to four acute child
health conditions if exclusive BF rates were to increase
from 7% to 45% at 4 months and if babies fed breast
milk at discharge from neonatal units increased from
35% to 75%. The conditions examined include gastro-
intestinal (GI) infection, acute otitis media, lower
respiratory tract infection and necrotising enterocolitis.
In addition, the cost-savings and value of life-time health
gains for mothers from associated reductions in breast
cancer were estimated to exceed £31million for each
annual cohort of women.9 Childhood obesity, sudden
infant death and cognitive outcomes—all conditions
with important economic implications—were also found
to be adversely affected by not BF, though given the
nature of the available evidence it was not possible to
attribute speciﬁc cost-savings from increased BF rates
with regard to these conditions.9
BF and public health
Increasing BF rates is a priority in all four UK countries.
In England, BF is a priority White Paper public health
policy with the potential to impact on health inequalities,
and the 6–8-week BF rate is an outcome in the Public
Health Outcomes Framework.10 BF is also a Department
of Health ‘Vital Signs’ target10 and one of 20 key National
Health Service (NHS) operating plan performance mea-
sures. The National Institute for Health and Care
Excellence (NICE) guidance11 recommends a multistrate-
gic approach to increase BF rates. There are therefore
strong drivers within the NHS for the identiﬁcation of
successful strategies to improve BF rates.
Results of development and feasibility testing stages
This trial forms the third stage of a research project
exploring the potential of ﬁnancial incentives to
increase BF in areas with low rates.
The ﬁrst stage developed the idea, assessed the accept-
ability of the ﬁnancial incentive ‘shopping vouchers for
BF’ scheme in principle, agreed the components of the
scheme with local women12 and midwives, health
visitors,13 and obtained permissions from the relevant
authorities to test the scheme.
The second stage assessed the feasibility (acceptability
and implementation) of the scheme in the real world
in three small areas (an electoral ward in North
Derbyshire, a ‘neighbourhood’ in Shefﬁeld and a town-
ship in Rotherham). The main ﬁndings14 were that mid-
wives and health visitors were willing to alert women to
the scheme, and co-sign application forms and voucher
claims; and that women joined the Nourishing Start for
Health (NOSH) scheme, claimed vouchers and pre-
ferred supermarket and high street vouchers to vouchers
for local independent shops.
Aim of the study
The aim of the study is to evaluate the effectiveness of a
ﬁnancial incentive scheme (NOSH) designed to in-
crease BF rates in wards with low BF rates using a cluster
(electoral ward) randomised trial with mixed-method
process and content evaluation.
METHODS, DESIGN AND ANALYSIS
Study objectives
The primary objective is to test the impact of the offer
of the NOSH intervention on 6–8 weeks BF rates in clus-
ters (with low BF rates <40% BF at 6–8 weeks).
The secondary objectives are to: (1) test the impact of
the intervention on BF rates at initiation in clusters with
low BF rates; (2) examine the impact of the intervention
on a range of disease outcomes, and impact on health
service use in children aged 0–6 months; (3) determine
the resource use and costs of providing the intervention
by BF initiation, 6–8 weeks and 6 months; (d) examine
the cost-effectiveness of the intervention (incremental
cost per percentage point change in BF) at 6–8 weeks in
wards with low 6–8-week BF rates (<40% at 6–8 weeks),
accounting for costs associated with a monetary offer
made up to 6 months postbirth and costs saved in chil-
dren aged 0–6 months; and (e) examine the interaction
between the effectiveness and cost-effectiveness of the
intervention and a range of ward-level characteristics, to
estimate the incremental cost-effectiveness of interven-
tion over an extended time horizon, using an economic
model-based analysis.
Study design and setting
The trial design is an open pragmatic cluster rando-
mised controlled trial (cRCT) with a mixed-methods
process and context evaluation and an economic evalu-
ation. Clusters (2011 electoral wards) are randomised to
either: (1) offer of a ﬁnancial incentive scheme to
women who live in a designated cluster (intervention
arm) or (2) no offer (control arm; ﬁgure 1).
Districts are deﬁned as the whole (or sometimes
part) of a local government council (eg, Metropolitan
Borough Council, City Council or a County Council). In
order for a district to be eligible, the district must have:
▸ Electoral wards with low BF rates (<40% at 6–8 weeks);
▸ Not be currently providing ﬁnancial incentives to
breast feed;
▸ Provide approvals for midwives and health visitors to
help deliver the scheme.
The intervention
The intervention to be trialled is a behaviour change
intervention in the form of the offer of a structured
ﬁnancial incentive (shopping vouchers each worth
2 Relton C, et al. BMJ Open 2016;6:e010158. doi:10.1136/bmjopen-2015-010158
Open Access
£40×5) to women over a 6-month period—the NOSH
scheme. The intervention will be introduced into the
clusters randomised to the offer group through the dis-
tribution of NOSH scheme posters and booklets (via
children’s centres, GP surgeries, post ofﬁces and other
public places in the intervention cluster wards); a press
release to the local media, brieﬁng notes and invitations
to attend induction sessions about the NOSH scheme to
all healthcare providers involved in the provision of
infant feeding support services in the intervention clus-
ters. These include midwives, health visitors, BF support
workers and BF peer support workers. Information and
materials about the NOSH scheme are provided to mid-
wifery and health visiting teams working in the trial
intervention wards. Midwives and health visitors will
discuss the NOSH scheme with women during routine
contact. Taking part in the NOSH scheme is voluntary;
women are able to freely join and leave the NOSH
scheme. To join the NOSH scheme women complete an
application form which must be co-signed by their
healthcare provider. On approving the application form,
the NOSH ofﬁce (based at the University of Shefﬁeld)
will forward a ‘welcome pack’. This contains ﬁve NOSH
claim forms for vouchers each worth £40 to be signed
when the baby is 2 days, 10 days, 6 weeks, 3 months and
6 months) if the baby is still BF and/or receiving breast
milk. The ‘welcome pack’ also contains a NOSH fridge
magnet, and the NOSH booklet (ﬁgure 2) detailing
information about the scheme and details of local
support services in case of problems. Women will sign
and date each NOSH claim form if her baby is still
receiving breast milk and ask their healthcare provider
to co-sign the NOSH claim form. The NOSH ofﬁce will
aim to send vouchers to mothers by return post. The
intervention will be offered for babies born between 17
February 2015 and 17 February 2016.
Verification of BF in order to receive vouchers
The current method used in the UK to collect routine
data on infant feeding relies on information exchanged
between mother and her healthcare provider. The con-
sensus from the extensive consultation with local stake-
holders during an earlier stage of the NOSH project was
that veriﬁcation of BF should be conﬁrmed by a signed
statement from the mother and a signed statement from
their healthcare provider on the voucher claim forms.
If a healthcare provider has concerns that the baby is
not receiving any breast milk, then the healthcare pro-
vider can complete and send in a separate ‘expression
of concern form’ detailing their concerns. However, it is
vital that the NOSH scheme does not compromise the
existing relationship between the mother and the
Figure 1 NOSH trial schema. BF, breastfeeding; NOSH, Nourishing Start for Health; NHS, National Health Service.
Relton C, et al. BMJ Open 2016;6:e010158. doi:10.1136/bmjopen-2015-010158 3
Open Access
healthcare provider, thus all claims will be paid regard-
less of whether or not concerns have been expressed by
the healthcare provider. Analysis of the ‘expression of
concern’ cards will inform understanding of the reliabil-
ity of the veriﬁcation method.
Sampling frame and recruitment
The sampling frame for the trial is clusters (electoral
wards) with low BF rates (<40% at 6–8 weeks) in ﬁve dis-
tricts (Shefﬁeld, North Derbyshire, Rotherham, Doncaster
and Bassetlaw). Clusters (2011 electoral wards) in each
district were screened for eligibility using the most recent
data on BF available, when planning the trial. Following
randomisation, a total of 92 clusters (ﬁgure 3) were
included in the trial with a total estimated number of
10 833 births for the 1-year trial period.
Inclusion and exclusion criteria for scheme participants
All women aged 16 years and over, ordinarily resident in
each ward, and with an estimated date of delivery
between 18 February 2015 and before the end of the
trial period on 17 February 2016 will be eligible to apply
to join the NOSH scheme. No exclusion criteria are sti-
pulated; exclusion will be determined on a case-by-case
basis by healthcare providers using their clinical
judgement.
Randomisation
The cluster random allocation sequence was generated
by the study statistician (SW), who was not involved in
the enrolment of clusters, using computer-generated
random numbers, stratiﬁed by district, of variable block
size. The random allocation sequence was implemented
by CR who assigned the clusters (wards) to the
interventions. There is no blinding of trial participants,
care providers, outcome assessors or data analysts.
Outcomes
The primary outcome measure is the cluster-level
6–8-week BF period prevalence over the intervention
time period (1 April 2015 to 31 March 2016). BF will be
deﬁned as any BF (and will include babies who are
receiving supplementary food as well as BF, and exclu-
sively breastfed babies). The primary outcome will use
routine 6–8 week BF data analysed at cluster (electoral
ward) level. Secondary outcomes include BF initiation
period prevalence; exclusive BF rate; number and length
of admissions to hospital with: GI tract infection, otitis
media, respiratory tract infection, necrotising enterocoli-
tis and any (all) hospital admissions.
Data collection
Data used in this study will come from several sources,
measured at a cluster level (deﬁned by postcode) includ-
ing local routine data from district public health depart-
ments and local NHS Trusts on BF rates, census data
and Hospital Episode Statistics (HES) with further
linkage to health resource groups. We will use routine
data to determine cluster-level 6–8-week BF prevalence
(these data are based on healthcare provider’s profes-
sional judgement, after discussion with the mother).
Cluster (ward)-level descriptive data will be collected
using demographic data from the 2011 census, midyear
population estimates and deprivation data from the
English Index of Deprivation. Cluster-level covariates will
include deprivation (Index of Multiple Deprivation
(IMD) 2010), mother’s age, ethnicity, birth rate (from
local routine data sources), 6–8-week BF rate routine
Figure 2 NOSH vouchers for breastfeeding booklet. NOSH, Nourishing Start for Health.
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data collected from public health and child health infor-
mation services. Cluster secondary outcome measures
from routine data will include BF initiation and exclusive
BF, and number and length of hospital admissions.
Risk to accessing primary outcome data
The transfer of the commissioning of the 0–5 Healthy
Child Programme from the NHS to local authorities in
October 2015 may impact on the trial’s access to routine
6–8-week BF data. Although national systems are being
set up to ensure good routine data collection for 6–
8-week BF prevalence, local organisational challenges
may mean that data availability and quality varies by dis-
trict/provider.
Sample size
The primary outcome measure is cluster-level 6–8-week
BF period prevalence over the intervention time period.
The intra class correlation (ICC) (0.01) was estimated
from the most recently available 6–8-week BF rates in
the clusters in the sampling frame. Based on data from
92 clusters and an estimated 10 833 births per year, the
mean cluster size was 118. The proportion of babies
being breast fed at 6–8 weeks was estimated as 27.6%
(2985/10 833).
Assuming a 4% point increase in 6–8-week BF rates
between the intervention and comparator groups repre-
sents a clinically/practically important difference; an
ICC of 0.01; average cluster size of 118 births and a
mean 6–8-week BF rate of 28% in the control arm, then
with 4463 births per group (8926 in total) the trial is
powered to detect a 4% point increase in BF rates (from
28% to 32%) as statistically signiﬁcant at the 5% (two-
sided) level and 80% power. For a cRCT, this will require
a minimum of 76 clusters to be randomised (38 clusters
per group).
Data analysis plan
Statistical methods
As the trial is a parallel group cRCT, with a usual
(control) treatment arm, data will be reported and pre-
sented according to the revised CONSORT statement
for cRCTs.15 All statistical exploratory tests will be two-
tailed with α=0.05. The analysis will be performed on an
intention to treat basis. The analysis of the outcome data
will be carried out at the cluster level, using aggregate
cluster-level summary data on BF rates for each cluster,
as we will not have individual-speciﬁc mother-level
outcome data.
Figure 3 RCT districts, intervention and control clusters (electoral wards). RCT, randomised controlled trial.
Relton C, et al. BMJ Open 2016;6:e010158. doi:10.1136/bmjopen-2015-010158 5
Open Access
The primary objective is to evaluate the clinical effect-
iveness of the intervention (NOSH Scheme) compared
with a usual care control group, in new mothers, on BF
rates at 6–8 weeks in clusters with low BF rates (<40% at
6–8 weeks). Aggregate cluster-level summary BF rates, at
6–8 weeks will be compared, between the intervention
and control groups, using a multiple linear regression
model with regression coefﬁcients estimated by weighted
ordinary least squares.
The primary analysis will be a multiple linear regres-
sion model with terms for the baseline cluster BF rate,
district, randomised group and will be weighted with a
weight which is proportional to the inverse of the vari-
ance of the estimated BF rate outcome. The effective-
ness of the NOSH intervention in the intervention
period will be tested by the size and signiﬁcance of the
group term in the multiple linear regression model. A
95% CI for the group term for BF at 6–8 weeks between
the intervention and control group will be reported,
from the model, along with its associated p value.
A sensitivity analysis will be performed alongside this
primary analysis and will include additional baseline
cluster-level covariates, such as cluster-level deprivation
(IMD 2010); cluster-level age and ethnicity as deﬁned
above; cluster-level birth rate; cluster-level maternal
smoking rate at delivery in the multiple linear regression
model. Again a 95% CI for the group term for BF at
6–8 weeks between the intervention and control group
will be reported, from the model, along with its asso-
ciated p value. This estimate will be plotted alongside
the primary analysis estimate in a meta-analysis-style
forest plot graph. Secondary cluster-level outcomes
(eg, BF initiation) will be analysed in a similar way with
a similar model for the primary outcome. Any missing
cluster-level primary outcome (BF at 6–8 weeks) data will
be imputed using a variety of imputation methods
including last observation carried forward, regression
and multiple imputation.
An exploratory subgroup analysis will be performed
using multiple linear regression with the primary outcome,
summary BF rates at 6–8 weeks, as the response. We will
use an interaction statistical test between the randomised
intervention group and subgroup to directly examine
the strength of evidence for the difference between treat-
ment group (intervention vs control) varying between
subgroups. District, cluster-level age (% women aged
16–44 years), ethnicity (% non-white) and socio-
economic deprivation will be the only prior deﬁned sub-
groups to be considered for interaction test. Subgroup
analysis will be performed regardless of the statistical sig-
niﬁcance on the overall intervention effect. The regres-
sion coefﬁcients for the interactions between treatment
group and each subgroup will be presented with the
associated CIs and p values.
Economic evaluation
The base case within-trial cost-effectiveness analysis will
compare the NOSH offer made to women over a
6-month period postbirth versus no offer made, from a
healthcare provider perspective. It will be tied to the
primary outcome at 6–8 weeks and reported as cost per
percentage point change in BF rates at cluster level.
Cost will account for changes in resource use from the
intervention and consequences of changes in health
service use. Data collection will include (1) costs that do
not vary by cluster or participant (eg, time spent setting
up and negotiating coverage of the voucher scheme)
and need to be apportioned to clusters; (2) costs that
may vary by cluster but not by individual participant (eg,
induction and training of staff); (3) costs that vary by
participant (eg, number of vouchers sent, contacts made
to NOSH ofﬁce) that can be grouped by cluster. These
data will be sourced using diaries, interviews, administra-
tive records and the contact logging system at the NOSH
ofﬁce. Resource use consequences of the offer will
reﬂect the difference in resource use impacts from hos-
pital admissions for a range of acute conditions (GI
infections, otitis media, respiratory tract infections,
necrotising enterocolitis) in babies aged 0–6 months.
Cluster-level HES on inpatient and emergency admis-
sions will be converted into the relevant health resource
group code using a reference costs code to group and a
unit cost assigned according to the national reference
costs.16 Other resource use will be valued using unit
costs based on NHS reference costs16 and other national
averages, for example, PSSRU 2014,17 to generate
nationally generalisable estimates.
The incremental cost-effectiveness analysis will be
based on regression models ﬁtted separately for costs
and the primary outcome, accounting for correlation
between costs and effects and missing data where appro-
priate. The unit of analysis, as that of the effectiveness
analysis, will be cluster level. The regression-based ana-
lyses controlling for covariates and cluster effect will be
used to estimate changes in BF, health service use and
costs between trial arms.
Deterministic sensitivity and scenario analysis will
explore: the impact of using all admissions rather than
admissions for the four selected conditions; the poten-
tial roll-out of the NOSH scheme; and a subgroup ana-
lysis may be included if appropriate. Probabilistic
sensitivity analysis will estimate precision of the cost-
effectiveness estimates and present cost-effectiveness
acceptability curves and compute incremental net
beneﬁt statistics for speciﬁc values of decision-makers
willingness to pay (WTP) for per cent-point change in
BF rates. Beyond-trial modelling of longer term expecta-
tions for cost-effectiveness will be undertaken,
with methods reported elsewhere. We will explore the
possibility of generating a cost per QALY in the
decision-analytic model-based analysis.
Intervention process and context evaluation
Process and context evaluation helps researchers to dis-
tinguish between results that are due to the intervention
succeeding or failing, and those that may be inﬂuenced
6 Relton C, et al. BMJ Open 2016;6:e010158. doi:10.1136/bmjopen-2015-010158
Open Access
by the social/organisational context or implementation
of the intervention. Such evaluations are especially valu-
able in community-based trials.18 19 Where a cluster
design is used, an additional value resides in the ability of
an evaluation to assess the impact of the local context on
the implementation of the intervention in each setting
(cluster ward). This is likely to be particularly relevant to
trials of public health initiatives as the negative conse-
quences of the environment, resource shortages, organ-
isational change, competing demands and leadership can
affect an organisation’s ability to effectively deliver an
intervention.20 21 The process/context evaluation will also
be used to explore any unintended consequences of the
intervention.
Monitoring of the process and delivery of the interven-
tion will be conducted using a mixture of qualitative and
quantitative methods. Individual-level data will be sought
on the views of healthcare providers, commissioners,
funders and policymakers regarding the process of deli-
vering the intervention and the completeness and accur-
acy of the routinely collected 6–8-week BF data using
interviews and focus groups. Topic guide reﬁnement,
sampling strategies, and data collection and analysis will
be iterative to address the speciﬁc research questions.
Awareness of the intervention and views and experiences
of the intervention will be collected using interviews and
focus groups with mothers and social media.
Qualitative data analysis
NVivo software package will be used to enable complex
organisation and retrieval of qualitative data. Framework
analysis22 will be used to analyse the data in order to
enhance understanding of social phenomena in order
to inﬂuence social policy in the UK. Concepts, categor-
ies and themes will be identiﬁed and coded before com-
parison with other data to provide analytical categories.
Dissemination
Local authority Research Governance permissions have
been obtained for healthcare providers in the ﬁve trial
districts to participate.
TRIAL STATUS
Data collection is ongoing.
DISCUSSION
The results of this large cRCT will be used to inform
commissioners and other public health decision-makers
about the acceptability, effectiveness and cost-effectiveness
of behaviour change support in the form of ﬁnancial
incentives to mothers to breast feed in areas with low BF
rates. This trial will add to the growing body of knowledge
on the role of ﬁnancial incentives in public health. If the
intervention is found to be effective, then this would con-
tribute to future policy discussions on how ﬁnancial for
BF might be used to improve the long-term health of the
population, reduce the risk of disease and obesity in
infancy, childhood and adulthood.
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